What is Peginesatide: Uses, Dosage, Side Effects and More

Peginesatide is a synthetic medication that was designed to treat anemia in people with chronic kidney disease who are on dialysis. It works by stimulating your bone marrow to produce more red blood cells, similar to how your body's natural hormone erythropoietin functions. However, this medication was withdrawn from the market in 2013 due to serious safety concerns, including severe allergic reactions that led to hospitalizations and deaths.

What is Peginesatide?

Peginesatide was a man-made protein medication that mimicked the action of erythropoietin in your body. Erythropoietin is a hormone your kidneys naturally produce to signal your bone marrow to create red blood cells. When your kidneys are damaged from chronic disease, they can't make enough of this hormone, leading to anemia.

The medication was specifically developed for people with chronic kidney disease who were receiving dialysis treatment. It was given as an injection once a month, which was more convenient than other similar medications that required more frequent dosing. Unfortunately, peginesatide is no longer available for use due to safety issues that emerged after its approval.

What was Peginesatide used for?

Peginesatide was used to treat anemia in adults with chronic kidney disease who were on dialysis. Anemia happens when you don't have enough healthy red blood cells to carry oxygen throughout your body, leaving you feeling tired, weak, and short of breath.

People with kidney disease often develop anemia because their damaged kidneys can't produce enough erythropoietin. This creates a cycle where your body struggles to make the red blood cells it needs. Peginesatide was designed to step in and provide that missing signal to your bone marrow.

The medication was only approved for patients already receiving dialysis treatment. It wasn't intended for people with milder kidney disease or those not yet on dialysis. Your doctor would have considered this option if other treatments weren't working well enough to manage your anemia symptoms.

How did Peginesatide work?

Peginesatide worked by binding to the same receptors in your bone marrow that respond to natural erythropoietin. Think of it as using a key that fits the same lock your body's natural hormone would use. Once attached, it triggered your bone marrow to start producing more red blood cells.

The medication was considered a strong treatment option because it could significantly increase red blood cell production. However, this strength also meant it needed careful monitoring to prevent your red blood cell levels from rising too quickly or too high, which could cause dangerous complications.

Your body would typically start responding to peginesatide within a few weeks, though it could take up to three months to see the full effect. The medication stayed active in your system for about a month, which is why it only needed to be given once monthly.

How should Peginesatide have been taken?

Peginesatide was given as an injection either into a vein (intravenously) or under the skin (subcutaneously) once a month. Your healthcare provider would have administered this medication during your dialysis session or at a medical facility. It wasn't something you could take at home on your own.

The injection didn't require any special preparation regarding food or drink. You could eat normally before and after receiving the medication. Your doctor would have determined the right dose based on your weight, current red blood cell levels, and how well you were responding to treatment.

Before each injection, your healthcare team would have checked your blood pressure and reviewed your recent lab results. They would also watch you carefully for any signs of allergic reactions, especially during your first few doses when reactions were most likely to occur.

How long should Peginesatide have been taken?

The duration of peginesatide treatment would have varied depending on your individual response and tolerance to the medication. Most people would have continued treatment as long as their anemia persisted and the medication was helping without causing significant side effects.

Your doctor would have monitored your red blood cell levels closely, typically checking them every few weeks initially, then monthly once your levels stabilized. If your anemia improved significantly or if you experienced concerning side effects, your doctor might have adjusted the dose or considered switching to a different treatment.

Since peginesatide was withdrawn from the market, anyone who was taking it would have been switched to alternative anemia treatments. Your healthcare team would have worked with you to find the best replacement therapy for your specific situation.

What were the side effects of Peginesatide?

Peginesatide carried several potential side effects, ranging from mild to life-threatening. The most serious concern was severe allergic reactions, which led to the medication being removed from the market. These reactions could be immediate and dangerous, requiring emergency medical treatment.

Common side effects that people experienced included:

• Muscle spasms and pain
• Back pain
• Cough
• High blood pressure
• Diarrhea
• Nausea
• Swelling in arms or legs

These everyday side effects were generally manageable and often improved as your body adjusted to the medication. However, they still needed to be reported to your healthcare team.

The serious side effects that ultimately led to peginesatide's withdrawal were severe allergic reactions called anaphylaxis. These reactions could cause difficulty breathing, severe drop in blood pressure, swelling of face and throat, and could be fatal if not treated immediately. Some people also experienced serious cardiovascular problems, including heart attacks and strokes.

Blood clots were another significant concern, particularly in the access sites used for dialysis. The medication could also cause your red blood cell levels to rise too quickly, leading to dangerously high blood pressure and other complications.

Who should not have taken Peginesatide?

Several groups of people should not have taken peginesatide, even when it was available. Anyone with a known allergy to peginesatide or any of its components should have avoided this medication completely. People with uncontrolled high blood pressure were also not good candidates for treatment.

Pregnant and breastfeeding women were advised against using peginesatide due to insufficient safety data. The medication's effects on developing babies weren't fully understood, making it too risky for use during pregnancy or while nursing.

People with certain types of cancer, particularly those affecting the blood or bone marrow, should not have used peginesatide. The medication could potentially stimulate cancer cell growth in these cases. Additionally, anyone with a history of severe allergic reactions to similar medications would have been at high risk.

Those with active infections or inflammatory conditions might have needed to wait until these issues were resolved before starting treatment. Your immune system's response to peginesatide could be unpredictable when dealing with other health challenges simultaneously.

Peginesatide brand name

Peginesatide was sold under the brand name Omontys in the United States. This was the only brand name under which the medication was marketed before its withdrawal from the market in 2013.

The medication was developed by Affymax and marketed in partnership with Takeda Pharmaceuticals. It received FDA approval in March 2012 but was voluntarily recalled by the manufacturers in February 2013 due to serious safety concerns.

Peginesatide alternatives

Several alternatives to peginesatide are available for treating anemia in people with chronic kidney disease. These medications work similarly by stimulating red blood cell production, but they have different safety profiles and dosing schedules.

The most commonly used alternatives include:

• Epoetin alfa (Epogen, Procrit) - given 1-3 times per week
• Darbepoetin alfa (Aranesp) - given weekly or every other week
• Methoxy polyethylene glycol-epoetin beta (Mircera) - given monthly

These medications have been used longer than peginesatide and have more established safety records. Your doctor will choose the best option based on your specific needs, how often you can come in for injections, and how well you tolerate each medication.

Iron supplements are often used alongside these medications to ensure your body has enough iron to make healthy red blood cells. Some people may also benefit from blood transfusions in certain situations, though this is typically reserved for severe cases.

Was Peginesatide better than Epoetin alfa?

Peginesatide and epoetin alfa were both effective at treating anemia in people with chronic kidney disease, but they had different advantages and disadvantages. Peginesatide's main advantage was its once-monthly dosing schedule, compared to epoetin alfa's need for 1-3 injections per week.

In terms of effectiveness, studies showed that peginesatide was able to maintain hemoglobin levels just as well as epoetin alfa. Both medications could successfully treat anemia and reduce the need for blood transfusions in most patients.

However, peginesatide's safety profile proved to be significantly worse than epoetin alfa's. The severe allergic reactions that led to peginesatide's withdrawal were not commonly seen with epoetin alfa, which has been used safely for many years. This makes epoetin alfa the better choice overall, despite requiring more frequent injections.

Today, epoetin alfa remains a standard treatment option with a well-established safety record. While the convenience of monthly dosing was appealing, the serious risks associated with peginesatide ultimately made it unsuitable for continued use.